Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00850681 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

A Phase 1 study of Actinic Keratosis, sponsored by Peplin.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT00850681 is a Phase 1 study of Actinic Keratosis that has completed, run by Peplin. The registered enrollment target is 50 participants, below the 186-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00850681, a Phase 1 study of Actinic Keratosis, has completed, sponsored by Peplin.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This Phase 1 study is designed to determine the photoallergic potential of PEP005 Gel, 0.01% and it's vehicle on normal skin.

Conditions Studied

Interventions

  • DRUG PEP005 (ingenol mebutate) Gel

Study Locations (1)

New Jersey

  • TKL Research, Inc. - Paramus

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2009-02
Est. Completion 2009-04
Phase Phase 1

Sponsor

Peplin

19 total trials

What the Registry Record Tells You About NCT00850681

The ClinicalTrials.gov registry entry for NCT00850681 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (73% lower). The listed sponsor is Peplin, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 1 intervention - of which PEP005 (ingenol mebutate) Gel is the first listed.

NCT00850681 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00850681 about?

NCT00850681 is a clinical study titled "A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers". This Phase 1 study is designed to determine the photoallergic potential of PEP005 Gel, 0.01% and it's vehicle on normal skin.

What is the current status of trial NCT00850681?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2009-02. Estimated completion is 2009-04.

What conditions does trial NCT00850681 study?

This clinical trial studies the following conditions: Actinic Keratosis.

What interventions are being tested in trial NCT00850681?

The interventions under investigation include: PEP005 (ingenol mebutate) Gel (DRUG).

Who is sponsoring clinical trial NCT00850681?

This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00850681 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.